Global nutrition company, Herbalife Ltd. (NYSE:HLF), announced that leading Czech gastroenterologist, Dr. Pavel Kohout, has been appointed to its Nutrition Advisory Board (NAB). Dr. Kohout brings more than 23 years of experience in clinical nutrition and metabolism to Herbalife, and will support the company’s activities in the Czech Republic and Slovakia.

“Dr. Kohout is a recognized and respected expert in nutrition, and we are pleased to welcome him to our board,” said Dr. David Heber, chairman, Nutrition Advisory Board. “Obesity rates continue to rise around the world, and as a result, Herbalife has an increasingly important responsibility to help promote nutrition education and training. We look forward to working with Dr. Kohout to advance our objective of providing independent Herbalife members with the tools and knowledge to positively impact the health and lives of their friends, families and communities around the world.”

“I am thrilled to join a company so focused on providing access to good nutrition for communities around the globe,” said Dr. Kohout. “I look forward to partnering closely with Herbalife members to ensure they have the information they need to help their customers lead healthy and active lives.”

The Herbalife NAB is comprised of leading experts from around the world in the fields of nutrition and health who inform, educate and train Herbalife members and customers on the principles of good nutrition, physical activity and leading a healthy lifestyle. The NAB is chaired by David Heber, M.D., Ph.D., F.A.C.P., F.A.S.N., chairman, Herbalife Nutrition Institute and Founding Director, Center for Human Nutrition, UCLA*. (Original Source)

Shares of Herbalife closed last Friday at $43.83 . HLF has a 1-year high of $69.69 and a 1-year low of $27.60. The stock’s 50-day moving average is $37.70 and it’s 200-day moving average is $38.98.

On the ratings front, Herbalife has been the subject of a number of recent research reports. In a report issued on March 13, BTIG analyst April Scee maintained a Buy rating on HLF, with a price target of $55, which implies an upside of 25.5% from current levels. Separately, on March 2, Canaccord Genuity’s Scott Van Winkle reiterated a Buy rating on the stock and has a price target of $42.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, April Scee and Scott Van Winkle have a total average return of 5.8% and 15.6% respectively. Scee has a success rate of 75.0% and is ranked #1378 out of 3574 analysts, while Winkle has a success rate of 62.5% and is ranked #147.

The street is mostly Bullish on HLF stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $55.60, which represents a potential upside of 26.9% from where the stock is currently trading.

Herbalife Ltd is a nutrition company. The Companyalong with its subsidiariessells weight management, targeted nutrition, energy, sports & fitness, and outer nutrition products.